PubMed Health⌕ Search

Biomedical subjects

Jesper Olsen

Publications and source records attributed to Jesper Olsen.

4 recordsLinked to original sources
PubMed2006

Human neutrophil peptides 1, 2 and 3 are biochemical markers for metastatic colorectal cancer.

Colorectal cancer (CRC) patients have increased levels of human neutrophil peptides 1-3 (HNP1-3) in tumour tissue and plasma. The aim is to study whether the amount of HNP1-3 in tumour and plasma from CRC patients correlate with Dukes' stages A-D. The amount of HNP1-3 in tumour tissue, normal colonic mucosa, and plasma was determined with mass spectrometry. Plasma levels of HNP1-3 were determined with enzyme-linked immuno-sorbent assay (ELISA). The amount of HNP1-3 determined with mass spectrometry was increased in tumours compared to normal colonic tissue in CRC patients in Dukes' stage A-D, whereas HNP1-3 in plasma was only elevated in Dukes' stage D compared to healthy individuals. HNP1-3 plasma concentration determined with ELISA was increased in Dukes' stages C and D, but not in A and B. It is concluded that HNP1-3 is a potential marker for prognostic assessment, surveillance of patients, and monitoring chemotherapy in CRC patients with advanced disease.

Adult↗
PubMed2006

Preanalytical and analytical variation of surface-enhanced laser desorption-ionization time-of-flight mass spectrometry of human serum.

BACKGROUND: Surface-enhanced laser desorption-ionization time-of-flight (SELDI-TOF) mass spectrometry of human serum is a potential diagnostic tool in human diseases. In the present study, the preanalytical and analytical variation of SELDI-TOF mass spectrometry of serum was assessed in healthy individuals. METHODS: Serum and plasma were obtained from healthy human individuals. Protein peaks in human serum and plasma were determined by SELDI-TOF mass spectrometry. RESULTS: The protein peaks in serum in healthy individuals showed no variation with gender, age, fasting, or diurnal rhythm. The intensity of protein peaks changed significantly during clotting of serum from 30 to 60 min, followed by smaller changes from 60 to 120 min. The intensity of protein peaks changed after 60-min storage of serum at room temperature, whereas no changes were observed for storage on ice. The number of reproducible protein peaks in serum was determined on WCX2, SAX2, and IMAC30 arrays as 29, 34, and 36, respectively. The average coefficient of variation (CV) of the mass value of protein peaks was 0.03%. The intra-assay CV of peak intensity on IMAC30 arrays was 16% (10%-36%, n=8) for 36 peaks, inter-assay CV was 18% (6%-34%, n=4) for 16 peaks, and inter-individual CV was 38% (16%-56%, n=16) for 20 peaks. CONCLUSIONS: The pre-analytical and analytical conditions of SELDI-TOF mass spectrometry of serum have a significant impact on the protein peaks, with the number of peaks low and the assay variation high. Consequently, SELDI-TOF mass spectrometry of serum needs further evaluation before application in clinical diagnostics.

Age Factors↗
PubMed2005

Upregulated expression of human neutrophil peptides 1, 2 and 3 (HNP 1-3) in colon cancer serum and tumours: a biomarker study.

BACKGROUND: Molecular markers for localized colon tumours and for prognosis following therapy are needed. Proteomics research is currently producing numerous biomarker studies with clinical potential. We investigate the protein composition of plasma and of tumour extracts with the aim of identifying biomarkers for colon cancer. METHODS: By Surface Enhanced Laser Desorption/Ionisation--Time Of Flight/Mass spectrometry (SELDI-TOF/MS) we compare the protein profiles of colon cancer serum with serum from healthy individuals and the protein profiles of colon tumours with normal colon tissue. By size exclusion chromatography, we investigate the binding of HNP 1-3 to high mass plasma proteins. By microflow we investigate the effect of HNP 1-3 on mammalian cells. RESULTS: Human Neutrophil Peptides -1, -2 and -3 (HNP 1-3), also known as alfa-defensin-1, -2 and -3, are present in elevated concentrations in serum from colon cancer patients and in protein extracts from colon tumours. A fraction of HNP 1-3 in serum is bound to unidentified high mass plasma proteins. HNP 1-3 purified from colon tumours are lethal to mammalian cells. CONCLUSIONS: HNP 1-3 may serve as blood markers for colon cancer in combination with other diagnostic tools. We propose that HNP 1-3 are carried into the bloodstream by attaching to high mass plasma proteins in the tumour microenvironment. We discuss the effect of HNP 1-3 on tumour progression.

Animals↗